C. diff. Spores and More

Join us with our guests;

With Doctor Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA

Associate Professor of Medicine,Division of Infectious Diseases, Corporate Medical Director, Infection Prevention,Epidemiology,and Antibiotic Stewardship ,DMC and WSU Director,Infection Prevention,Epidemiology and Antibiotic Stewardship,Vibra Hospital

Dr. Chopra will lead the discussion with an overview of a C. difficile infection followed by Alba Muhlfeld, and Renata Johnson, C. diff. Survivors both sharing their journey and providing key-points to our global listeners.

Join us with our guests from Seres Therapeutics as they discuss the latest news

on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study results were equally compelling when characterized by the alternative metric of sustained clinical response, where 88.9% of patients in the SER-109 arm achieved this objective. The study’s efficacy results exceeded the statistical threshold previously provided in consultation with the U.S. Food and Drug Administration (FDA) that could allow this single clinical study to fulfill efficacy requirements for a Biologics License Application (BLA). The SER-109 safety results were favorable, with an adverse event profile comparable to placebo. Listen in and learn more from the leading topic experts.

Dr. Tamas Haidegger, Ph. D., Associate Professor Obuda University, and

Co-founder: HandInscan will be discussing the importance of not only hand-washing but how Hand Hygiene is the top priority in social safety. Hand Hygiene remains the number one infection prevention action individuals can utilize worldwide to prevent the spread of germs and viruses worldwide. Dr. Haidegger will also introduce the research and science behind the HandInScan - an objective hand hygiene control in the medical environment.

Join us with our guest Dr. Robert Carman, Ph. D., Director of Microbiology at TECHLAB, Inc. Dr. Carman's research focuses on Clostridioides difficile (C. diff., C. difficile, CDI).

Dr. Carman not only introduces us to the gut microbiome, but explains the details of the environment, the colonies of microorganisms, bacteria, viruses, protozoa, and fungi, that are present in the gastrointestinal tract

Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST

Senior Infection Preventionist with

Clorox Professional Products Co.

Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.

Join us with Guest; Doe Kley, RN, CIC, MPH,T-CHEST

Senior Infection Preventionist with

Clorox Professional Products Co.

Ms. Kley will be discussing the importance of knowing the key-points in transitioning from an acute-care facility, long-term facility, and intermediate healthcare facility to the home environment.

Join us with our guest:

Candida Fratazzi, MD, Consulting Medical Director at Vedanta Biosciences, focused on pioneering rational design of drugs, made of defined consortia of bacteria, to Modulate the Human Microbiome.

Dr. Fratazzi will be discussing and explaining Microbiome functions and how its changes impact our health. How bacteria colonies’ equilibrium is supported and supports our immune system. Thus, the need to correct imbalance of bacteria colonies not with untargeted pull of bacteria such as fecal transplant or with a single strain of bacteria such as probiotics. Dr Fratazzi will certainly be educating us on this episode, Why Bacterial Consortia May Stop C. diff. Recurrences”

Welcome to Episode 6 of 6; of the 8th Annual International C. diff. Post-Conference Special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics while focusing on the leading HAI - Clostridioides difficile We will hear from the following keynote speakers:

Camilla S. Graham, MD, MPH, Ri-Co-DIFy: Summit's Ridinilazole Phase 3 Trial to Advance the Sciences in the Treatment of C. difficile and Reduction of Recurrence.

Maureen Spencer, RN, M.Ed., CIC, Engaging Middle School Children In Infection Prevention Through the C Diff Foundation's Junior Infection Fighters Program.

Alba Muhlfeld, C. diff. Survivor, Patient's Journey.

Erik Dubberke, MD, MSPH, Optimizing Prevention of Hospital-Onset

Clostridioides difficile Infection.

Many of the presentation slides are available to view/download until January 14th, 2021 located on the dedicated conference website: www.cdiff2020.com

Welcome to Episode 5 of 6; of the 8th Annual International C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD). We will hear from the following keynote speakers

Barbara McGovern, MD, ECOSPORIII: A Phase 3 Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of SER-109, an Investigational Microbiome Therapeutic for the Treatment of Patients w/Recurrent Clostridioides difficile Infection (rCDI).

Glenn Tillotson, Ph.D., FRSM, FCCP, It's a Small World w/C. diff. - a One Health Perspective.

Dayle Skelly, C. diff. Survivor, A Patient's Journey.

Many of the presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations.

Welcome to Episode 4 of 6; of the 8th Annual International C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual, collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD). We will hear from three leading topic-experts:

Mark Wilcox, MD, FRCPath, DNA Fingerprinting to Understand C. difficile Transmission in Hospitals.

Caterina Oneto, MD, Patient Support; In-Person, and Through the Global TeleSupport Network.

Sahil Khanna, MBBS, MD, Microbiome Restoration; Getting One Step Closer Every Day!

Many of the presentation Slides are available until January 14th, 2021 on www.cdiff2020.com

We hope you enjoy the presentations from the leading speakers of the 8th Annual

Int'l C. diff. Conference & Health EXPO.

This audio broadcast is sponsored by Summit Therapeutics